LifeStance Health Group (NASDAQ:LFST) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

LifeStance Health Group (NASDAQ:LFST) released its quarterly earnings data on Thursday. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.05, Briefing.com reports. The company had revenue of $312.70 million during the quarter, compared to analyst estimates of $302.25 million. LifeStance Health Group had a negative net margin of 13.05% and a negative return on equity of 10.51%. LifeStance Health Group’s revenue for the quarter was up 18.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.17) EPS. LifeStance Health Group updated its FY 2024 guidance to EPS and its Q4 2024 guidance to EPS.

LifeStance Health Group Price Performance

LFST stock opened at $7.36 on Friday. The firm has a 50 day moving average of $6.92 and a 200-day moving average of $6.21. The firm has a market capitalization of $2.82 billion, a P/E ratio of -17.95 and a beta of 1.24. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 0.20. LifeStance Health Group has a 12 month low of $4.64 and a 12 month high of $9.20.

Insider Activity at LifeStance Health Group

In related news, insider Ann Varanakis sold 5,269 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $6.28, for a total value of $33,089.32. Following the sale, the insider now directly owns 263,007 shares of the company’s stock, valued at $1,651,683.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

LFST has been the subject of a number of recent research reports. UBS Group decreased their price target on shares of LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating for the company in a research note on Thursday, August 15th. Barclays reduced their target price on shares of LifeStance Health Group from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.25.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.